Finoriq

Finoriq research workspace

Aclarion, Inc. (ACON) Historical Metrics

Aclarion, Inc. operates as a healthcare technology company in the United States. Review ACON fundamentals, ratios, and historical filing metrics on Finoriq.

Company Snapshot

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Company
Aclarion, Inc. (ACON)
Ticker
ACON
Market Cap
$6.4M
Latest Price
$2.60
Industry
Medical Devices

Open insider transactions

Aclarion, Inc. (ACON) Current Valuation Metrics

Static valuation preview for Aclarion, Inc. (ACON). Market data retrieved 2026-07-09. Filing currency USD.

MetricValueSource
P/SMarket cap divided by latest TTM revenue.92.0xRevenue | TTM Q1 2026
Earnings YieldLatest TTM net income divided by market cap.-112.3%Net Income | TTM Q1 2026
Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap.-101.8%Operating Cash Flow | TTM Q1 2026
Price / BookMarket cap divided by stockholders' equity.0.36xStockholders' Equity | Q1 2026

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.